an extended-release version of hydromorphone, Palladone, was available before being voluntarily withdrawn from the market after a July 2005 FDA advisory warned of a high overdose potential when taken with alcohol. As of March 2010, it is still available in the United Kingdom under the brand name Palladone SR, Nepal under the brand name Opidol, and in most other European countries, In Canada, prescription continuous release hydromorphone is available as both brand name (Hydromorph Contin) and generic formulations (Apo-Hydromorphone CR).

Pharmacokinetics